63V fundamentals

Verici Dx Plc operates as a developer of advanced clinical diagnostics in organ transplant. It offers the following products for clinical validation and commercialization: Clarava and Tuteva. The Clarava product is a pre-transplant prognosis for the risk of early acute rejection. The Tuteva product is a post-transplant diagnostic focused upon acute cellular rejection, including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatinine levels. The company was founded on April 22, 2020 and is headquartered in Franklin, TN.